Immunotherapy in Melanoma | Specialty

Expert Discusses Mutations in Melanoma

October 19th 2017

Alan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.

Dr. Daud on Challenges Facing the Treatment Landscape for Melanoma

October 19th 2017

Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

FDA Grants Priority Review to Adjuvant Nivolumab in Melanoma

October 18th 2017

The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Intralesional Combinations Pave the Way for Melanoma Treatment

October 18th 2017

The use of intralesional therapies in combination with checkpoint inhibitors has shown to be an improvement to monotherapy and combinations with immunotherapy in melanoma.

Dr. Luke on Impactful Data in the Field of Melanoma

October 10th 2017

Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses impactful data in the field of melanoma.

Expert Addresses Ongoing Challenges in Melanoma

October 3rd 2017

Merrick I. Ross, MD, discusses ongoing challenges in melanoma, including treating liver metastases, the diminished yet important role of surgery, and the need for better biomarkers.

Dr. Postow on Combination Regimens for High-Risk Melanoma

September 28th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combinations of regimens for patients with high-risk melanoma.

Dr. Weber on CheckMate-238 Compared With Other Trials in Melanoma

September 28th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the results of CheckMate-238 compared with other adjuvant trials for patients with melanoma.

Relatlimab/Nivolumab Combo Active in Melanoma After PD-1/PD-L1 Therapy

September 26th 2017

Half of patients with melanoma who progressed on anti-PD-1/PD-L1 therapy benefited from the combination of nivolumab and the LAG-3 inhibitor relatlimab.

COMBI-AD: Implications for Melanoma Patients

September 22nd 2017

A New Standard for Stage 3 BRAF+ Melanoma

September 22nd 2017

Avelumab Approved in Europe for Merkel Cell Carcinoma

September 21st 2017

The European Commission has approved avelumab (Bavencio) for the treatment of patients with metastatic Merkel cell carcinoma.

Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma

September 20th 2017

The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.

FDA Accepts Filing for Binimetinib/Encorafenib Combo in BRAF+ Melanoma

September 14th 2017

The FDA has accepted new drug applications supporting use of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for BRAF-mutant advanced, unresectable or metastatic melanoma.

Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common

September 13th 2017

Nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

Disease-Free Survival Gains Reported for Vemurafenib in Stage IIC-IIIB Melanoma

September 13th 2017

Adjuvant therapy with vemurafenib for high-risk melanoma led to mixed results, as patients with stage IIIC or later did not benefit, but those with earlier stage disease did.

Dr. Dummer on COMBI-AD Trial Results in BRAF-Mutant Melanoma

September 13th 2017

Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

Nivolumab Superior to Ipilimumab as Adjuvant Therapy for Stage III/IV Resected Melanoma

September 12th 2017

Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

September 11th 2017

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Dr. Weber on CheckMate-238 for Melanoma

September 11th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the CheckMate-238 trial for patients with melanoma.